CD68+/CD163+巨噬细胞产生的CCL2作为显微镜下多血管炎相关间质性肺病的候选临床生物标志物
本研究纳入49例ANCA阳性显微镜下多血管炎(MPA)患者(其中32例合并间质性肺病)和10例健康对照,比较16种血清生物标志物。发现MPA-ILD组初始血清CCL2水平显著高于单纯MPA组,且与治疗后一年纤维化评分增加正相关;免疫组化显示MPA-ILD肺组织中CD68+/CD163+巨噬细胞和化生上皮细胞表达CCL2。结论提示CCL2与MPA-ILD发病相关,可能作为诊断和预测疾病进展的标志物。
要点
- MPA-ILD患者初始血清CCL2水平显著高于无ILD的MPA患者。
- 初始血清CCL2水平与治疗后一年纤维化评分增加正相关。
- MPA-ILD肺组织中CD68+/CD163+巨噬细胞和化生上皮细胞表达CCL2。
核心结论
- CCL2与MPA-ILD发病相关,可能作为诊断和预测MPA-ILD进展的有用标志物。
研究设计与样本
- 纳入49例ANCA阳性MPA患者(32例合并ILD)和10例健康对照,比较16种血清生物标志物。
- ILD通过高分辨率CT评估,采用磨玻璃影和纤维化评分。
- 对3例肺活检组织进行苏木精-伊红染色和免疫染色。
主要发现
- MPA-ILD组初始血清CCL2水平显著高于MPA组。
- MPA-ILD患者免疫抑制治疗1年后血清CCL2水平显著高于治疗前。
- 初始血清CCL2水平与治疗后一年纤维化评分增加正相关,并与初始血清血小板衍生生长因子水平正相关。
- 免疫组化显示MPA-ILD肺组织中CD68+/CD163+巨噬细胞和化生上皮细胞有强烈CCL2信号。
临床怎么用
- 血清CCL2可能用于辅助诊断MPA-ILD并预测纤维化进展。
- 靶向肺泡CD68+/CD163+巨噬细胞产生的CCL2可能成为ANCA阳性MPA-ILD的治疗干预方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Microscopic polyangiitis (MPA) is often complicated by interstitial lung disease (ILD); however, biomarkers that can be used to diagnose and predict the progression of MPA-ILD have not been identified. In this study, we evaluated various serum biomarkers in MPA-ILD to assess their diagnostic and predictive performance. METHODS: We enrolled 49 patients with anti-neutrophil cytoplasmic antibody (ANCA)+ MPA and 10 healthy controls, with 32 of the MPA patients also presenting ILD. The presence of ILD was assessed by high-resolution CT and evaluated by ground-glass opacity and fibrosis score. We compared 16 biomarker profiles among MPA-ILD patients, those without ILD, and healthy controls and extracted biomarkers with higher levels in MPA-ILD groups to determine correlations with disease activity and other biomarkers. Three lung biopsies were examined by haematoxylin-eosin staining and immunostaining. RESULTS: Initial serum C-C motif chemokine ligand 2 (CCL2) levels were significantly higher in the MPA-ILD group than those of the MPA group, and were significantly higher in MPA-ILD patients 1 year after immunosuppressive therapy than those before treatment. Initial serum CCL2 levels positively correlated with an increased fibrosis score during the year after treatment and with initial serum platelet-derived growth factor levels. Immunohistochemical staining showed intense CCL2 signals in CD68+/CD163+ macrophages and metaplastic epithelial cells in MPA-ILD lungs. CONCLUSION: CCL2 is associated with MPA-ILD pathogenesis and suggested its potential efficacy as a useful marker for diagnosing and predicting MPA-ILD progression. Therefore, targeting CCL2 in alveolar CD68+/CD163+ macrophages might represent a therapeutic intervention in ANCA+ MPA-ILD.
引用
- Matsuda S, Kotani T, Kuwabara H, et al. CCL2 produced by CD68+/CD163+ macrophages as a promising clinical biomarker of microscopic polyangiitis-interstitial lung disease. Rheumatology (Oxford). 2021. PMID: 33493350. doi:10.1093/rheumatology/keab064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。